Wednesday 21 January 2015

» Marathon Pharmaceuticals announce FDA fast track designation for deflazacourt Action Duchenne

» Marathon Pharmaceuticals announce FDA fast track designation for deflazacourt Action Duchenne: "Marathon Pharmaceuticals, LLC, a biopharmaceutical company focused on developing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for deflazacort in the treatment of patients with Duchenne Muscular Dystrophy (DMD). Deflazacort is a glucocorticoid with anti-inflammatory and immunosuppressant properties."



'via Blog this'

No comments:

Post a Comment